|
Patent landscape, scope, and claims: |
United States Drug Patent 4,384,123: Scope, Claims, and Landscape Analysis
What is United States Patent 4,384,123?
United States Patent 4,384,123, titled "3-acyloxy-2-azetidinones," was granted on May 17, 1983. The patent application was filed on September 29, 1981, by Merck & Co., Inc. [1]. The patent describes a class of chemical compounds and their use as intermediates in the synthesis of beta-lactam antibiotics. Specifically, it focuses on 3-acyloxy-2-azetidinones that are substituted at the 1-position with an alkyl or aryl group and at the 4-position with a substituent containing a protected hydroxyl group. These compounds are characterized by the presence of an acyloxy group at the 3-position of the azetidinone ring [1].
What are the Key Claims of Patent 4,384,123?
The claims of Patent 4,384,123 define the specific inventions protected by the patent. The primary claims focus on the composition of matter of the novel chemical compounds and their utility as synthetic intermediates.
-
Claim 1: This independent claim defines a specific class of 3-acyloxy-2-azetidinones. The structure includes:
- A 2-azetidinone ring system.
- An acyloxy group (R'COO-) at the 3-position, where R' is an alkyl or aryl group.
- A substituent at the 1-position, which can be an alkyl group, a benzyl group, or a substituted benzyl group.
- A substituent at the 4-position, which is a group of the formula -(CH2)n-X, where n is an integer from 0 to 3, and X is a substituent containing a protected hydroxyl group. The protected hydroxyl group can be a silyl ether, an ester, or a ketal.
- The claim also specifies that the 4-position substituent may include a sulfur atom, with a protecting group attached [1].
-
Claim 2: This dependent claim further refines Claim 1, specifying that in the 3-acyloxy-2-azetidinone of Claim 1, the substituent at the 1-position is a benzyl group or a substituted benzyl group [1].
-
Claim 3: This dependent claim narrows the scope of Claim 1 to instances where the acyloxy group at the 3-position is derived from a carboxylic acid having from 1 to 5 carbon atoms [1].
-
Claim 4: This independent claim covers a process for the preparation of the compounds claimed in Claim 1. The process involves reacting a 3-hydroxy-2-azetidinone intermediate with an acylating agent in the presence of a base [1].
-
Claim 5: This independent claim defines a method for synthesizing beta-lactam antibiotics. The method utilizes the 3-acyloxy-2-azetidinones claimed in Claim 1 as key intermediates. The process involves cleaving the acyloxy group and further functionalizing the molecule to form the desired antibiotic [1].
-
Claim 6: This dependent claim specifies that the beta-lactam antibiotics synthesized by the method of Claim 5 are carbapenems or penems [1].
What is the Scope and Utility of Patent 4,384,123?
The scope of Patent 4,384,123 is primarily directed towards novel chemical structures and their application in organic synthesis. The core utility lies in the synthesis of advanced beta-lactam antibiotics.
Chemical Structure Scope
The patent covers a specific subclass of 3-acyloxy-2-azetidinones. The structural features that define this subclass are critical to understanding its scope. The azetidinone ring is the central beta-lactam core. The substituents at the 1, 3, and 4 positions are precisely defined. The acyloxy group at the 3-position serves as a leaving group or a protected hydroxyl functionality that can be readily transformed. The substituents at the 1 and 4 positions are designed to allow for further synthetic elaboration towards complex antibiotic structures.
Synthetic Utility
The primary utility of the compounds claimed in Patent 4,384,123 is as advanced intermediates in the synthesis of beta-lactam antibiotics, particularly carbapenems and penems. These antibiotic classes are known for their broad spectrum of activity and efficacy against many resistant bacterial strains.
- Carbapenems: These are a class of beta-lactam antibiotics characterized by a fused ring system that includes a carbapenem nucleus. Examples include imipenem, meropenem, and ertapenem.
- Penems: These are also a class of beta-lactam antibiotics, structurally related to carbapenems, with a fused ring system containing a penem nucleus. Examples include faropenem and ritipenem.
The 3-acyloxy-2-azetidinones described in the patent provide a strategic entry point for constructing the complex polycyclic structures of these antibiotics. The acyloxy group can be selectively manipulated, and the protected hydroxyl group at the 4-position allows for the introduction of side chains crucial for antibiotic activity.
What is the Patent Landscape for 3-Acyloxy-2-azetidinones and Related Antibiotics?
The patent landscape surrounding United States Patent 4,384,123 is complex, involving numerous patents that cover:
- Novel Beta-Lactam Structures: Patents claiming new antibiotic compounds within the carbapenem, penem, cephalosporin, and penicillin classes.
- Synthesis Intermediates: Patents protecting specific intermediate compounds used in the synthesis of these antibiotics. Patent 4,384,123 falls into this category.
- Synthetic Processes: Patents covering novel or improved methods for manufacturing antibiotic compounds, including stereoselective synthesis and purification techniques.
- Formulations and Delivery Systems: Patents related to pharmaceutical compositions, dosage forms, and methods of administration for beta-lactam antibiotics.
- Therapeutic Uses: Patents claiming the use of existing or novel antibiotics for treating specific infections or conditions.
Key Companies and Their Patent Activity
Several pharmaceutical companies have been active in patenting innovations related to beta-lactam antibiotics and their synthesis.
- Merck & Co., Inc.: As the assignee of Patent 4,384,123, Merck has a historical interest in this area. Their broader patent portfolio likely includes subsequent developments in carbapenem and other antibiotic research.
- Shionogi & Co., Ltd.: This company has a significant patent history in carbapenem antibiotics, including the development of meropenem. Their patents cover novel carbapenem structures and synthetic routes.
- Wyeth (now part of Pfizer): Wyeth was a major player in antibiotic development, with substantial patent filings related to various beta-lactam classes.
- Sanofi-Aventis (now Sanofi): Sanofi has a broad portfolio in infectious diseases, including patented antibiotics and their manufacturing processes.
- AstraZeneca: This company has also filed patents related to novel antibacterial agents and their synthetic pathways.
Patent Expirations and Generic Competition
United States Patent 4,384,123 expired in 2000, 20 years from its filing date. However, the compounds and processes claimed in this patent were likely used to synthesize commercial antibiotics. The patent protection for those final antibiotic products would have been based on separate patents covering the specific active pharmaceutical ingredients (APIs), their formulations, and their medical uses.
The expiration of foundational patents like 4,384,123 allows for generic manufacturers to utilize similar synthetic routes, provided they do not infringe on unexpired patents covering novel intermediates, specific process steps, or final drug products. The market for older antibiotics, including some carbapenems, has seen significant generic competition.
Key Technological Trends in the Landscape
- Stereoselective Synthesis: A major focus has been on developing highly stereoselective synthetic methods to obtain the correct enantiomers and diastereomers of beta-lactam antibiotics. Patents often claim novel chiral catalysts, reagents, or asymmetric synthesis routes.
- Novel Carbapenem and Penem Structures: Continuous research aims to discover new carbapenem and penem derivatives with improved pharmacological properties, such as enhanced stability against beta-lactamases, broader spectrum of activity, or better pharmacokinetic profiles.
- Combating Antibiotic Resistance: A significant driver for patenting is the development of antibiotics effective against multidrug-resistant (MDR) bacteria. This includes novel beta-lactams and combinations with beta-lactamase inhibitors.
- Process Optimization: Patents also cover improvements in manufacturing processes, such as higher yields, reduced costs, fewer purification steps, and greener chemistry approaches.
How has the Patent Landscape Evolved Since 4,384,123?
Since the grant of Patent 4,384,123 in 1983, the patent landscape for beta-lactam antibiotics and their synthesis has seen substantial evolution driven by scientific advancements, market demands, and the persistent challenge of antibiotic resistance.
Early Carbapenem Development and Patenting: Patent 4,384,123 was granted during a period of significant innovation in carbapenem chemistry. Following its filing, numerous patents emerged covering specific carbapenem derivatives, such as imipenem (patented by Merck) and later meropenem (patented by Shionogi). These patents focused on the final API structures and their specific therapeutic applications.
Advancements in Synthetic Methodologies: The initial synthetic routes, some of which may have been enabled by intermediates like those in 4,384,123, have been refined. Subsequent patents have focused on:
- Chiral Synthesis: Developing highly enantioselective and diastereoselective methods for constructing the beta-lactam core and its side chains. This includes patented asymmetric catalysis, enzymatic resolutions, and the use of chiral auxiliaries.
- Convergent Synthesis: Designing synthetic strategies where complex fragments are synthesized separately and then coupled, often leading to higher overall yields and efficiency. Patents have claimed novel coupling reactions and intermediate fragments for these convergent approaches.
- One-Pot Reactions: Innovations in process chemistry have led to the development of sequential one-pot reactions, reducing the number of isolation and purification steps. These improvements are often the subject of process patents.
Expansion to Broader Beta-Lactam Classes: While 4,384,123 specifically addresses intermediates for carbapenems and penems, the broader beta-lactam landscape has continued to expand. Patents have been filed for novel cephalosporins and monobactams with unique structural modifications designed to overcome resistance mechanisms or improve pharmacokinetic properties.
Response to Antibiotic Resistance: The increasing prevalence of antibiotic-resistant bacteria has spurred a new wave of innovation and patenting. This includes:
- Beta-Lactamase Inhibitors: Development and patenting of novel beta-lactamase inhibitors that, when co-administered with beta-lactam antibiotics, restore their efficacy. Examples include clavulanic acid, sulbactam, tazobactam, and avibactam. Patents often cover the inhibitors themselves, their combination products, and their therapeutic uses.
- Novel MOAs: While less common for traditional beta-lactams, research into novel mechanisms of action that can bypass common resistance pathways is ongoing, with potential for future patent filings.
- Targeting Specific Resistant Pathogens: Patents may claim antibiotics or combination therapies specifically designed to combat difficult-to-treat resistant organisms like carbapenem-resistant Enterobacteriaceae (CRE).
Regulatory and Market Influences:
- Orphan Drug Designations: Companies may seek patents and market exclusivity for antibiotics targeting rare infections or specific resistant strains through orphan drug pathways.
- Post-Grant Patent Challenges: The pharmaceutical industry frequently engages in post-grant patent challenges (e.g., inter partes review in the US) to invalidate patents that may hinder generic competition. The validity and scope of older patents are often scrutinized.
- Patent Linkage and Exclusivity: Regulatory frameworks, such as the Hatch-Waxman Act in the US, create a complex interplay between patent protection and market exclusivity for drug products.
Current Research and Future Directions:
The ongoing research in this field is increasingly focused on:
- Broad-Spectrum Agents: Developing antibiotics effective against a wide range of Gram-positive and Gram-negative bacteria, including those with intrinsic or acquired resistance.
- Combination Therapies: Exploring synergistic combinations of existing or novel agents to enhance efficacy and overcome resistance.
- Alternative Delivery Mechanisms: Patenting novel formulations and delivery systems that improve drug penetration to infection sites or reduce systemic toxicity.
The patent landscape, therefore, is not static. It reflects a continuous cycle of innovation, competition, and adaptation to evolving clinical and scientific challenges. While Patent 4,384,123 provided a foundational contribution to carbapenem synthesis, subsequent patenting activities have built upon this foundation, addressing new challenges and expanding the therapeutic armamentarium against bacterial infections.
Key Takeaways
- United States Patent 4,384,123, granted in 1983, claims novel 3-acyloxy-2-azetidinone compounds and their use as intermediates in the synthesis of beta-lactam antibiotics, particularly carbapenems and penems.
- The patent's claims are specific to the chemical composition of matter and a process for preparing these intermediates, as well as a method for their use in antibiotic synthesis.
- The utility of the patented intermediates lies in their strategic role in constructing complex beta-lactam antibiotic structures, facilitating further synthetic elaboration.
- The patent expired in 2000, meaning the specific claims of 4,384,123 are no longer in force. However, its underlying technology contributed to the development of commercially significant antibiotics.
- The broader patent landscape for beta-lactam antibiotics is extensive, encompassing novel API structures, advanced synthetic processes, formulations, and therapeutic uses, with significant activity from major pharmaceutical companies.
- Subsequent innovations have focused on stereoselective synthesis, combating antibiotic resistance through novel structures and combinations (e.g., with beta-lactamase inhibitors), and process optimization.
Frequently Asked Questions
-
When did United States Patent 4,384,123 expire?
United States Patent 4,384,123 expired on May 17, 2000.
-
What specific classes of antibiotics are synthesized using intermediates claimed in Patent 4,384,123?
The patent claims are directed towards intermediates for the synthesis of carbapenem and penem antibiotics.
-
Does the expiration of Patent 4,384,123 allow for the free use of all related synthetic pathways for beta-lactam antibiotics?
No. While the specific claims of Patent 4,384,123 have expired, other unexpired patents may cover novel antibiotic compounds derived from these intermediates, alternative synthetic processes, specific formulations, or their therapeutic uses.
-
Who was the original assignee of United States Patent 4,384,123?
The original assignee of United States Patent 4,384,123 was Merck & Co., Inc.
-
Can current generic manufacturers use the specific chemical structures claimed in Patent 4,384,123?
As the patent has expired, the specific chemical structures claimed in Patent 4,384,123 are no longer protected. However, their use in the manufacture of specific commercial antibiotics may be subject to other existing, unexpired patents covering the final antibiotic compounds or their specific manufacturing processes.
Citations
[1] Merck & Co., Inc. (1983). 3-acyloxy-2-azetidinones. U.S. Patent 4,384,123. Washington, DC: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
